Pharmacy automation company ARxIUM declared on Tuesday that its RIVA systems have accurately and safely prepared more than 10 million IV doses across all global installations.

This represents the production of patient-specific and batch IV doses of syringes and bags in acute care hospitals, centralised pharmacies and cancer centres. The GMP RIVA system contains several new features that are designed to meet Current Good Manufacturing Practice regulations for environmental monitoring, disclosed the company.

According to the company, RIVA, the most advanced, fully automated IV compounding system available, increases patient safety by reducing errors and contamination and minimising pharmacy technicians' exposure to hazardous preparations. It reduces the cost-per-dose of medications, need for outsourcing and pharmacy waste. This has resulted in many installations achieving more than a 100% return on investment in less than three years due to substantial costs savings and operational efficiencies such as high capacity inventory, long batch runs and the elimination of manual processes.

Earlier this year, three RIVA systems began compounding medications at two 503B hospitals in Florida. Combined, the GMP RIVA systems have already produced more than 110,000 doses, revealed the company.

At the 2019 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition in Las Vegas, the company will showcase the updated GMP RIVA f from 9 December-11 December 2019 in booth 2019.